m+Medelevator.RU
← Поиск публикаций
Frontiers in aging neuroscience · 2026

Inflammaging and neurovascular unit dysfunction in cognitive ageing: mechanisms, biomarkers, and therapeutic opportunities.

СтатьяОбзорНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Bu Fan, Zeng Shulin, Lou Zhengchi, Zhou Sijia, Yang Xiufen, Wen Yi, Luo Weixiang, Qin Lan

Аннотация

Age-related cognitive decline is increasingly recognised as arising from interacting immune and neurovascular vulnerabilities rather than from isolated insults. In this Review, we synthesise current human and mechanistic evidence within a convergence framework in which inflammaging and neurovascular unit (NVU) dysfunction are conceptualised as a feedback-coupled system. Persistent immune remodelling may promote endothelial activation, redox imbalance, pericyte-astrocyte support failure, microglial priming, and impaired neurovascular coupling, thereby reducing cerebrovascular reserve and destabilising blood-brain barrier (BBB) selectivity and transport. Conversely, emerging NVU dysfunction may amplify neuroimmune signalling and increase the susceptibility of white matter and synapses to late-life injury. We organise the literature around three mechanistic interfaces-immune-endothelium, glia-vascular, and flow-metabolic-and assess how this framework may clarify biomarker stratification, mechanism-aligned endpoint selection, and heterogeneity of intervention responses. Current evidence is strongest for integrative plausibility across inflammatory, vascular, and cognitive domains, but remains more limited for temporal ordering, effect modification, and reversibility in humans. We highlight key uncertainties, including peripheral-to-central signalling, harmonisation of BBB metrics, and heterogeneity across mixed late-life pathologies, and assess the therapeutic implications of immune- and NVU-directed strategies.

ИП Урсолов Владлен Сергеевич

ИНН 500118482352 · ОГРНИП 314500117700049

Реквизиты и контакты